GlassScriptPhysician profile
Caitlin J Warf
NPI 1720329170
$6,638.30
in general payments reported to CMS, 2019-2025
44 companies · $1,494 in 2025
The $1,494 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $262 · 2020: $183 · 2021: $483 · 2022: $1,369 · 2023: $1,436 · 2024: $1,411 · 2025: $1,494.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,341.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,340.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,534.15 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Novo Nordisk INC | $1,058.77 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $672.22 | 2019-2025 | Jardiance, Stiolto Respimat, Synjardy |
| Lilly USA, LLC | $397.12 | 2021-2025 | Mounjaro, Zepbound, Amyvid |
| Amgen INC. | $322.17 | 2019-2025 | Repatha, Otezla, Evenity |
| Astrazeneca Pharmaceuticals LP | $278.73 | 2020-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $264.99 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Pfizer INC. | $186.51 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $164.74 | 2022-2025 | Spravato, Xarelto |
| E.R. Squibb & Sons, L.L.C. | $147.02 | 2020-2025 | Eliquis |
| Shield Therapeutics INC | $112.76 | 2023-2025 | Accrufer |
| Bayer Healthcare Pharmaceuticals INC. | $109.62 | 2021-2024 | |
| Exact Sciences Corporation | $101.79 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $95.02 | 2019-2023 | Belsomra, Steglatro |
| Dexcom, INC. | $93.38 | 2024-2025 | Dexcom G6 Transmitter |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caitlin Warf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.